Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov 3;5(1):260.
doi: 10.1038/s41392-020-00370-w.

Outsmarting SARS-CoV-2 by empowering a decoy ACE2

Milena Sokolowska  1   2
Affiliations
Comment

Outsmarting SARS-CoV-2 by empowering a decoy ACE2

Milena Sokolowska. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests.

Figures

Fig. 1
Fig. 1
Current approaches to neutralize SARS-CoV-2 spike protein and to prevent its binding to the cellular ACE2. a Cocktails of neutralizing antibodies against spike protein of SARS-CoV-2, peptide-based binders blocking SARS-CoV-2-RBD-ACE2 interface, small molecule inhibitors blocking the host cell proteases, and soluble recombinant human ACE2 are currently being under different stages of development against COVID-19. b Chan and colleagues engineered a stable soluble variant of ACE2 with enhanced binding affinity to the RBD of SARS-CoV-2 spike protein, sustained angiotensin-2 peptidase activity, and superior abilities to block SARS-CoV-2 infection in vitro. RBD receptor-binding domain. Created by Zuzanna Lukasik, MD
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Chan KK, et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020 doi: 10.1126/science.abc0870. - DOI - PMC - PubMed
    1. Baum A, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. - PMC - PubMed
    1. Monteil V, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–913. doi: 10.1016/j.cell.2020.04.004. - DOI - PMC - PubMed
    1. Kuba K, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11:875–879. doi: 10.1038/nm1267. - DOI - PMC - PubMed
    1. Radzikowska U, Ding M, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020 doi: 10.1111/all.14429. - DOI - PMC - PubMed

Publication types

Substances